| アブストラクト | BACKGROUND: There are limited data describing adverse infant outcomes in infants born to women with a low risk of complications during pregnancy, such as those who may be enrolled in maternal immunization trials. This retrospective study estimated incidence proportions of infant outcomes in different cohorts of liveborn infants in England between 2005 and 2017. METHODS: The incidence proportions of 10 infant outcomes were calculated for liveborn infants from pregnancies represented in the Clinical Practice Research Datalink (CPRD) Mother-Baby Link (MBL) and linkage to Hospital Episode Statistics (HES). Three infant cohorts were designed: (1) the all pregnancies infants cohort (N = 185,119), (2) the all pregnancies with a gestational age (GA) >/= 24 weeks infants cohort (N = 183,869), and (3) the low-risk pregnancies infants cohort (LR infants cohort, N = 121,871), which included pregnancies with a GA >/= 24 weeks and no diagnosis of predefined high-risk medical conditions until 24 weeks GA. RESULTS: The most common adverse infant outcome in the three infant cohorts was macrosomia (e.g., 1,085.9/10,000 live births in the LR infants cohort), followed by minor congenital anomalies (e.g., 800.6/10,000 in the LR infants cohort), very low/low birth weight (e.g., 400.6/10,000 in the LR infants cohort), and major congenital anomalies (e.g., 270.4/10,000 in the LR infants cohort). The incidence proportions for early-onset sepsis, very low/low birth weight, and minor and major congenital anomalies were lower in the LR infants than in the other cohorts (non-overlapping confidence intervals [CIs]). The incidence proportions of neonatal death, infant death, late-onset sepsis, macrosomia, small for GA, and large for GA were similar between cohorts (overlapping CIs). CONCLUSIONS: This study generated background rates of adverse infant outcomes from liveborn infants of all and low-risk pregnancies represented in the CPRD Pregnancy Register MBL and linkage to HES. The results indicate lower incidence proportions of several adverse infant outcomes in infants from low-risk pregnancies compared to all pregnancies, illustrating the importance of considering maternal risk factors. These background rates may facilitate the interpretation of safety data from maternal immunization trials and of pharmacovigilance data from maternal vaccines. They may also be of interest for other interventions studied in pregnant women. |
|---|
| ジャーナル名 | BMC pregnancy and childbirth |
|---|
| Pubmed追加日 | 2023/5/10 |
|---|
| 投稿者 | Riley, Megan; Lambrelli, Dimitra; Graham, Sophie; Henry, Ouzama; Sutherland, Andrea; Schmidt, Alexander; Sawalhi-Leckenby, Nicola; Donaldson, Robert; Stoszek, Sonia K |
|---|
| 組織名 | GSK, 14200 Shady Grove Rd, Rockville, MD 20850, USA. megan.x.riley@gsk.com.;Evidera, 201 Talgarth Rd, Hammersmith, W6 8BJ, London, UK.;GSK, 14200 Shady Grove Rd, Rockville, MD 20850, USA.;Present affiliation: Moderna, Cambridge, MA, USA.;Present affiliation: Bill & Melinda Gates Medical Research Institute, Cambridge,;MA, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37161382/ |
|---|
